Foley Partner Gardner Davis and Senior Counsel Danielle Whitley authored an article titled “NOL and void” in the April 5, 2010 issue of The Deal. The authors discuss a Delaware Court of Chancery decision that upheld Selectica Inc.’s selection of a shareholder rights plan, or poison pill, as a tool to protect its net operating loss carry forwards (NOLs), remarking that it is the first time that a Delaware court has reviewed a board’s decision to adopt a poison pill intended to guard NOLs. They add that the decision should not be interpreted as support for the suggestion that a board can safely adopt a poison pill in every circumstance, noting the court’s acknowledgment that shareholder rights plans must be subject to careful review.
Author(s)
Related Insights
May 29, 2026
Foley Viewpoints
SEC Proposes Significant Reforms to Registered Offering Framework
On May 19, 2026, the Securities and Exchange Commission (SEC) proposed sweeping amendments to its rules and forms governing registered…
May 29, 2026
Foley Corporate Governance Update
DExit One Year Later: An Assessment of SB21, the Continuing Pace of Reincorporation and the Maturation of Texas as a Corporate Domicile
When I last addressed the so-called DExit phenomenon, Delaware’s General Assembly had just enacted Senate Bill 21 in response to the growing concern that public companies, prompted by a series of decisions from the Delaware Court of Chancery, most prominently Tornetta v. Musk, were reconsidering their historical preference for incorporation in Delaware.
May 28, 2026
Foley Viewpoints
AI Transcription Tools in Health Care: What In-House Counsel Needs to Get Right
AI is changing health care faster than almost any other technology in recent memory. Among the most rapidly adopted applications are transcription tools that record encounters, convert speech to text, generate draft notes, and support scheduling, intake, triage, and other administrative workflows.